key: cord-0812663-muwaixwj
authors: Carrell, Robin; Travis, James
title: α 1-Antitrypsin and the serpins: variation and countervariation
date: 1985-01-31
journal: Trends in Biochemical Sciences
DOI: 10.1016/0968-0004(85)90011-8
sha: 3bdbca2c3d6aae4f032ec28b02b1dd78b80d1e52
doc_id: 812663
cord_uid: muwaixwj

Abstract α 1-Antitrypsin is a plasma protein which protects elastic tissue from proteolytic attack. Consequently, genetic deficiency, or the oxidation of its reactive centre in cigarette smokers can result in the degenerative lung disease emphysema. Structural studies explain the mechanisms involved and have also drawn attention to a new family of serine proteinase inhibitors. The specificity of each of these inhibitors is primarily dependent on a single amino acid at its reactive centre. Site-directed mutagenesis is enabling the production of specifically designed inhibitors for therapeutic use, including an improved replacement for α 1-antitrypsin deficiency.

ture is presumably designed to firmly fix and a~-antichymotrypsin is really a at-Antitrypsin is a relatively small the reactive centre in an exposed site, Leuserpin (an inhibitor of proteinases glycoprotein of Mr 51 000, with 394 and in its optimal 'substrate' configur-cleaving at a leucine). This terminology amino acid residues and three oligo-ation. This is a presumption because in allows concise description of each saccharide side chains 3. It readily dif-the cleaved structure the reactive centre inhibitor and avoids a misleading comfuses into the tissue spaces where it is sprung (like a mousetrap) with mitment to a target enzyme. One emforms 1:1 complexes with its target pro-methionine 358 at one end of the barrassing example of misnaming is a~teases, principally neutrophil elastase, molecule separated by some 69~ from antitrypsin itself, which is not primarily The complex of inhibitor and enzyme is serine 359 at the other. In the intact an inhibitor of trypsin. Similarly, a~subsequently removed from the circu-inhibitor, the sequence preceding antichymotrypsin is not primarily an lation and catabolized in the liver and methionine 358 must be plucked out inhibitor of chymotrypsin, but rather of spleen, from a 13-sheet to give a strained loop cathepsin G and the chymases. The The inhibitor is thought to trap the joining with serine 359 (Fig. 2) . Thus, ambiguity of the historical nomenclaprotease by presenting its reactive site the cleaved inhibitor is stable, and the ture is clearly illustrated by the recent as an ideal substrate ~. There is rapid uncleaved inhibitor is metastable, which recognition ~L of a homologue, in the .association between the enzyme and explains the difficulty in crystallizing the mouse, of human cq-antichymotrypsin. inhibitor, but negligible dissociation, native at-antitrypsin.

This mouse 'an-antichymotrypsin' has with consequent formation of a tightly This view of the molecule with an lysine rather than leucine at its reactive bound enzyme-inhibitor complex, exposed and strained reactive centre fits centre, making it a Lyserpin rather than The reactive site of al-antitrypsin is well with other observations, such as the a Leuserpin. Hence, it does not inhibit situated near its C-terminus, centred on vulnerability of the reactive site to cleav-chymotrypsin but is a highly effective a methionine residue at position 358. age by non-serine proteinases and the inhibitor of trypsin-like proteases. Complex formation with elastase is susceptibility of the reactive centre

The ability to recognize the reactive accompanied by proteolytic attack on methionine to oxidation, centre by homology has also allowed the the bond between this methionine and identification of putative inhibitory the adjacent serine at position 359. The Serpin snperfamily activity in two unexpected members of key role of methionine 358 in defining

It is now clear that there is a whole the serpin family. These are ovalbumin 5 the specificity of inhibition is indicated family of serine proteinase inhibitors and angiotensinogen'3 neither of which in Table I . For the serpins in general, that have diverged from an ancestral are known to have an inhibitory the reactive centre, or P, residue acts as inhibitor over a period of about 500 function. However, both retain homa bait for the appropriate serine protein-million years. The best documented ology about the reactive site -perhaps ase with an affinity that is familiar to homologies are those between aranti-ovalbumin is an Alaserpin and angioprotein chemists, i.e. methionine (or trypsin 3, antithrombin 9, and a,-tensinogen is a Glyserpin? valine) for elastase, lysine for trypsin, antichymotrypsin ~°, but there is increas-Angiotensinogen is a particularly inleucine for chymotrypsin, and arginine ing evidence lt'12 that the family will teresting addition to the family. It has a for thrombin, include most of the inhibitors that recognized physiological role as the This descriptive concept of the inhibi-control the major proteolytic cascades source of the small peptides that control tor as a trap, with the active centre of the body, such as coagulation, the blood pressure: angiotensin I and II. acting as a bait, is supported by the crystallographic structure of al-antitryp--y 58~~ff~,~/ff/~4.32AT Table 1 .

These are cleaved as a ten-residue Met aS8 One in ten ZZ homozygotes will have segment from the N-terminus of the ~ liver disease, usually in early infancy. molecule. This activity of angiotensino-3j ~) Whether this results directly from gen has highlighted the likelihood that accumulation of the Z protein in the in the serpins in general, the N-terminal I z 342 liver or is a consequence of the plasma tail of the molecule forms a second (a) deficiency of inhibitor is still being functional site. This tail is of variable debated. What is clear, however, is that length in the individual members of the set asa the lung disease is directly related to the family; it does not have ordered struc-/~ plasma deficiency. ture and is on the exterior of the molecule where it is accessible to cleav-Met Smoking and emphysema age. It is this N-terminal tail that is the i m ~ In the course of a lifetime, there is a likely ~4 candidate for the major heparin (b) 3sa gradual and irreversible loss of elasticity binding site in antithrombin. In oq-anti- Fig. 2. (a) The reactive centre at elrantitrypsin is of the lungs. Up to the age of thirty, the trypsin, N-terminal cleavage is a signifiexposed on a strained loop probably hinged on resi-lungs have an elastic volume of 3.5 litres cant cause of the microheterogeneity of due 342 (site of the Z mutation). most people will have some limitation of the inhibitor or whether the released lung function, and since there is conpeptides function as physiological

The experimental results fit well with siderable individual variation there will messengers, the histological changes ~9. The RNA be some who will have lost a sufficient Mutation, deficiency and disease message (mRNA) for the M and Z proportion of their elastic volume to Two genetic variations of the amino proteins can be readily extracted from give the crippling lung disease emphyacid sequence of oq-antitrypsin are of human liver and shown to be present in sema. The chances of getting emphyequivalent amounts. Addition of the sema are greatly increased if there is an particular importance; both are con-mRNAs to cell-free systems shows accelerated loss of capacity. A number fined to Europeans and result in a decreased plasma concentration of the equal translation and addition of oligo-of factors are likely to be involved but saccharide side chains for M and Z 21. two documented occurrences of accelerinhibitor. These are the S and Z deficiency variants which differ from the This is confirmed by injecting the ated loss are in heavy smokers and in normal M ~q-antitrypsin in the substi-mRNAs into the Xenopus oocyte; how-people with severe cq-antitrypsin detution of two different glutamic acids, ever, although thereisequalproduction ficiency; both groups have a mean and processing, there is decreased annual loss of 80 ml per year. Again, The product of the S deficiency gene secretion of the Z antitrypsin 22.

there is considerable individual vari-(264 Glu--,Val) j5 is present in about Whatever the mechanism involved, ation but the onset of emphysema, 60% of the concentration of the normal M gene, and that of the Z gene (342 the end result is the same -a significant which is an unlikely event in the normal deficiency of plasma at-antitrypsin, individual, becomes a likely event in the Glu---~Lys)lr'17 at 15%. The two glutamic About 4% of Europeans are hetero-heavy smoker and also in the individual acids substituted in these variants both form important salt bridges which zygotes for the Z defect, i.e. genotype with homozygous al-antitrypsin denormally stabilize the molecule and it is MZ, and nearly one in a thousand will ficiency. However, it becomes a certain have the severe ZZ or SZ deficiency, event in the c~rantitrypsin deficient not surprising that both variants have a

The homozygous ZZ individual is individual who also smokes -here the decreased stability, as measured by heat liable to develop liver and lung disease, loss of expiratory volume increases to stress. The loss of stability of the S variant is compatible with an increas~ed turnover of the nascent S polypeptide ~':~ ~ but the prime cause of its decreased i~ iiii~ production is likely to be the presence of 5' an aberrant intron splice site introduced i.~ by the point mutation ~8.

The more severe Z deficiency is of i;~r , great interest as it involves a defect in ~i~ the pathway of processing and secretion of the polypeptide. Electron microscopy ,~.~i"~! ~ shows a gross accumulation of Z cq-~ antitrypsin at the level of the rough-to-~. ::' smooth endoplasmic junction '9 (Fig. 3) .

~-~'ii~j.~. Thus, there is a partial blockage of incompletely processed arantitrypsin just before it enters the Golgi vesicles. processing suggests blockage of transport, rather than a failure of oligo- Fig. 3 . Electron micrograph of liver from a ZZ patient. The Z antitrypsin accumulates as large saccharide processing, amorphous granules in the endoplasmic reticulurn. 300 ml .per year and most in this group 1 2 3 4 5 will have emphysema by the age of forty and be dead before they are fifty-five :3.

This acceleration of the onset of emphysema is readily explained in Native terms of the current belief 24 that the elasticity of the lung is maintained by a balance between the release of destructive enzymes (principally elastase) and the protective effect of inhibitors (principally, a]-antitrypsin). The balance Oxidised between protease and antiprotease is destroyed by the genetic deficiency of PPE Plasma -PRtS Met Val ctl-antitrypsin. Genetic deficiency in o~I-AT oL1-AT yeast yeast combination with habitual smoking is double jeopardy, since smoking results Fig. 4 . Gelatine plate incorporating an inhibitor to give end-point measurements of porcine pancreatic in an increased concentration of leucoelastase activity before and after oxidation with chloramine T. The control activio', without inhibitor, is cytes in the lung and consequently shown in 1. Addition of both plasma (2) and yeast (4) In addition, smokers are subject to another risk factor, oxidative stress 25'z~', bacteria by discharging oxygen free-mutation. The results of analysis conthat inactivates antitrypsin. The investi-radicals, and (2) isolate the focus by firmed this in a most satisfying way 2s. gation of this oxidative inactivation has releasing proteases to give tissue lique-As predicted, there was a mutation of revealed a subtle control mechanism faction. This liquefaction can occur in the reactive centre methionine 358 of that is built into the reactive site of et]-the immediate vicinity of the inflam-oq-antitrypsin to arginine (Table I ). In antitrypsin. The realization that oxi-matory focus because the oxygen free effect, the inhibitor had been converted dation can inactivate tx~-antitrypsin has radicals released by the leucocytes in-from a Metserpin to an Argserpin, i.e. it also led to an understanding of a activate oq-antitrypsin by oxidizing its lost the ability to inhibit elastase and number of lung pathologies, in particu-reactive centre methionine. The oxygen became a highly effective inhibitor of lar the emphysema of the heavy, free-radicals have only a short radius of thrombin (Fig. 4) . cigarette smoker 24.

activity and beyond this area the The identification of a~-antitrypsin The reactive centre methionine of a]-unoxidized cq-antitrypsin readily neu-Pittsburgh raised the possibility of antitrypsin fits the active-site pocket of tralizes the elastase. In this way the engineering mutations of the reactive elastase and, therefore, functions as a vulnerability of the methionine becomes centre. The natural mutation in the bait for its entrapment. However, advantageous by allowing a defined Pittsburgh variant has produced a methionine is readily oxidizable to zone of elastase activity, potent anticoagulant with obvious methionine suiphoxide, which has a However, evolution has obviously not therapeutic applications. This potential considerably larger bulk and does not had time to adjust to the introduction has recently been achieved by Courtney readily fit into the elastase pocket. As a of cigarette smoking. Here the ability of and colleagues s who used site-specific consequence, oxidized ct~-antitrypsin is oxidants to switch off the inhibitory mutagenesis to give high yields of the 358 an ineffective inhibitor of neutrophil activity of Cxl-antitrypsin becomes arginine mutant in E. coli. By varying elastase. This provides a real problem as grossly disadvantageous because the the replacement amino acid it should be there are several situations where oxi-smoker has an accumulation of leuco-equally possible to engineer specific dative stress occurs, particularly in the cytes in the lungs and hence a combined inhibitors of the other serine proteinases exposed areas of the lung, sufficient to exposure to elastase release and oxi-of the complement and inflammatory give demonstrable inactivation of et]-dative inactivation of eq-antitrypsin, cascades. antitrypsin. This occurs with direct One immediate question ~'3 was exposure to oxidants, as in ozone poilu.-The Pittsburgh variant and site-directed whether it would be possible to produce tion or the therapeutic use of pure mutation an oxidation-resistant cq-antitrypsin. oxygen; it also occurs when there i,;

A theme of this review is that the Intravenous replacement therapy with excessive accumulation of leucocytes 2~' specificity of the serpins is primarily plasma concentrates of tx~-antitrypsin is as in the lungs of the heavy smoker, dependent on a single amino acid at already being tested on patients with the Why has evolution provided such a their reactive centre. The possibility that genetic deficiency. Meeting the worldvulnerable reactive centre for al-anti., this specificity of inhibition could be wide needs for such therapy will require trypsin? The answer seems to be thai: changed by altering the reactive centre microbial production of ct~-antitrypsin the ability to switch off arantitrypsin amino acid became a reality with using recombinant DNA techniques. provides a means by which essential the identification of an extraordinary Why not get the microbes to produce an tissue breakdown can occur in the natural mutation. This was found in a improved cq-antitrypsin? immediate vicinity of an inflammatory 14-year-old male from Pittsburgh with a

The obvious way of doing this ~'3 is to focus 3 and perhaps in areas of regrowth, severe bleeding disorder caused by replace the reactive centre methionine As an example, consider the tissue re-greatly increased antithrombin activity -~7. by a valine. Good yields of the 358 action to a thorn in the thumb. The The presence of an electrophoretically valine-cq-antitrypsin (Valserpin) have thorn is rapidly surrounded by leuco-abnormal at-antitrypsin suggested that been achieved in yeast by Hallewell and cytes which must: (1) kill any associated the disease was caused by an active-site colleagues 7, and in E. coli by other

Proc. Nail Acad. 29

 (Fig. 4) . The product 7 Rosenberg, S., Barr, P. J., Najarian, R. and J., eds), p. Among them is a family of carbohydrate structures that are related to the major Studies with monoclonal antibodies have shown that a family of blood group-related blood group antigens. They are the subantigens based on the carbohydrate backbone sequences Galf~l-4(or3)GlcNAc ject of thisreview, which examines their behave as tumour-associated antigens in certain cell types of certain individuals but as expression both on glycoproteins and normal antigens in others. Also, some of the rapid changes in antigenicity during glycolipids, their roles as receptors for embryogenesis result from structural changes in these saccharides. The saccharides are infective agents and as targets of antiborne on glycoproteins and glycolipids and there is evidence that they are associated receptor autoantibodies, and their poswith receptor systems such as the receptor glycoprotein for the epidermal growth sible roles as components of receptor factor. Sialyl-oligosaccharide sequences in this series are host-cell receptors for the systems for endogenous regulators of human pathogen Mycoplasma pneumoniae, and monoclonal autoantibodies pro-growth such as the epidermal growth duced following infection with this agent are directed against the backbone regions of factor.the receptor sequence.The advent of the hybridoma technique highly specific antibodies which would Antigens based on Type 2 backbones of Krhler and Milstein for producing single out components that distinguish In this field, as in others, certain monoclonal antibodies of desired speci-embryonic cells from those of adults, disease-associated phenomena have ficities rekindled hopes of generating precursor cells from their mature pro-provided important precedents. In the T. Feizi and R. A. Childs are at the Applied geny and tumour cells from their normal sera of patients with the autoimmune lmmunochemistry Research Group, Clinical counterparts. The potentialofsuchanti-haemolytic disorder known as cold Research Centre, Warlord Road, Harrow, Middlesex bodies in medicine and biology is enor-agglutinin disease (which is associated HA13UJ, UK.mous; for example, as diagnostic and with chronic lymphoproliferative dis-